Attack the tumor counterattack-c-Flip expression in Jurkat-T-cells protects against apoptosis induced by coculture with SW620 colorectal adenocarcinoma cells

Journal of Surgical Research

Volumn 176, Issue 1, 2012, Pages 133-140

  Steiert, Andreas E ^a,b   Sendler, Daniel ^a,b   Burke, Willam F ^a,b   Choi, Claudia Y ^a,b   Reimers, Kerstin ^a,b   Vogt, Peter M ^a,b  

^a Department of Plastic Hand and Reconstructive Surgery   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

apoptosis; colon carcinoma; FLICE inhibitory protein (FLIP); gene therapy; immunotherapy; tumor counterattack

Indexed keywords

FLICE INHIBITORY PROTEIN; LIPOCORTIN 5;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL SURVIVAL; COCULTURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HYPOTHESIS; IMMUNOFLUORESCENCE TEST; LEUKEMIA CELL LINE; MEDICAL LITERATURE; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; TUMOR COUNTERATTACK;

ADENOCARCINOMA; ANTIGENS, CD95; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL COMMUNICATION; COCULTURE TECHNIQUES; COLORECTAL NEOPLASMS; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, CELLULAR; JURKAT CELLS; MIDDLE AGED; TISSUE THERAPY; TRANSFECTION;

EID: 84862028098     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2011.06.023     Document Type: Article

References (75)

1. T. Kume, K. Oshima, and Y. Yamashita Relationship between Fas-ligand expression on carcinoma cell and cytotoxic T-lymphocyte response in lymphoepithelioma-like cancer of the stomach Int J Cancer 84 1999 339
2. G.P. Dunn, L.J. Old, and R.D. Schreiber The three Es of cancer immunoediting Annu Rev Immunol 22 2004 329
3. D. Loose, and C. Van de Wiele The immune system and cancer Cancer Biother Radiopharm 24 2009 369
4. Y. Kuang, X. Weng, and X. Liu Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses Cancer Lett 293 2010 254
5. D.H. Lynch, F. Ramsdell, and M.R. Alderson Fas and FasL in the homeostatic regulation of immune responses Immunol Today 16 1995 569
6. M. Moser, and K.M. Murphy Dendritic cell regulation of TH1-TH2 development Nat Immunol 1 2000 199
7. J.L. Gowans The lymphocyte-A disgraceful gap in medical knowledge Immunol Today 17 1996 288
8. H. Fujiwara, M. Fukuzawa, and T. Yoshioka The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity J Immunol 133 1984 1671
9. F. Gerosa, B. Baldani-Guerra, and C. Nisii Reciprocal activating interaction between natural killer cells and dendritic cells J Exp Med 195 2002 327
10. J.M. Kelly, P.K. Darcy, and J.L. Markby Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection Nat Immunol 3 2002 83
11. J. Zuo, T. Ishikawa, and S. Boutros Bcl-2 overexpression induces a partial epithelial to mesenchymal transition and promotes squamous carcinoma cell invasion and metastasis Mol Cancer Res 8 2010 170 182
12. F.H. Igney, and P.H. Krammer Immune escape of tumors: Apoptosis resistance and tumor counterattack J Leukoc Biol 71 2002 907
13. M.W. Bennett, J. O'connell, and G.C. O'sullivan Expression of Fas ligand by human gastric adenocarcinomas: A potential mechanism of immune escape in stomach cancer Gut 44 1999 156
14. M. Hahne, D. Rimoldi, and M. Schroter Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape Science 274 1996 Nov 1363
15. R. Yigit, L.F. Massuger, and C.G. Figdor Ovarian cancer creates a suppressive microenvironment to escape immune elimination Gynecol Oncol 117 2010 366
16. R. Watanabe-Fukunaga, C.I. Brannan, and N.G. Copeland Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis Nature 356 1992 314
17. J. Wu, T. Zhou, and J. He Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene J Exp Med 178 1993 461
18. J. O'Connell, G.C. O'Sullivan, and J.K. Collins The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand J Exp Med 184 1996 1075
19. Y. Kubota, K. Sunouchi, and M. Ono Local immunity and metastasis of colorectal carcinoma Dis Colon Rectum 35 1992 645
20. B. Cheng Association between up-regulation of Fas ligand expression and apoptosis of tumor-infiltrating lymphocytes in human breast cancer J Huazhong Univ Sci Technolog Med Sci 26 2006 573
21. T. Reimer, C. Herrnring, and D. Koczan FasL: Fas ratio - a prognostic factor in breast carcinomas Cancer Res 60 2000 822
22. M.W. Bennett, J. O'Connell, and G.C. O'Sullivan The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma J Immunol 160 1998 5669
23. M. Thome, P. Schneider, and K. Hofmann Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors Nature 386 1997 517
24. M. Sturzl, C. Hohenadl, and C. Zietz Expression of K13/v-FLIP gene of human herpes virus 8 and apoptosis in Kaposi's sarcoma spindle cells J Natl Cancer Inst 91 1999 1725
25. H.I. Cho, and E. Celis Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects Cancer Res 69 2009 9012
26. F.C. Kischkel, S. Hellbardt, and I. Behrmann Cytotoxicity-dependent APO-1 (Fas/CD95.-associated proteins form a death-inducing signaling complex (DISC) with the receptor EMBO J 14 1995 5579
27. J.P. Medema, C. Scaffidi, and F.C. Kischkel FLICE is activated by association with the CD95 death-inducing signaling complex (DISC) EMBO J 16 1997 2794
28. M. Muzio, A.M. Chinnaiyan, and F.C. Kischkel FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex Cell 85 1996 817
29. P.H. Krammer CD95(APO-1/Fas)-mediated apoptosis: Live and let die Adv Immunol 71 1999 163
30. J.H. Russell Activation-induced death of mature T cells in the regulation of immune responses Curr Opin Immunol 7 1995 382
31. D. Kabelitz, T. Pohl, and K. Pechhold Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes Immunol Today 14 1993 338
32. M. Irmler, M. Thome, and M. Hahne Inhibition of death receptor signals by cellular FLIP Nature 388 1997 190
33. C. Scaffidi, I. Schmitz, and P.H. Krammer The role of c-FLIP in modulation of CD95-induced apoptosis J Biol Chem 274 1999 1541
34. S. Wimmenauer, A. Steiert, and G. Wolff-Vorbeck Influence of cytokines on the expression of Fas ligand and CD44 splice variants in colon carcinoma cells Tumour Biol 20 1999 294
35. C.Y. Choi, K. Reimers, and C. Allmeling Inhibition of apoptosis by expression of antiapoptotic proteins in recombinant human keratinocytes Cell Transplant 16 2007 663
36. K. Mayer, M.E. Iolyeva, and U. Meyer-Grahle Intestine-specific expression of green fluorescent protein-tagged cathepsin B: Proof-of-principle experiments Biol Chem 389 2008 1085
37. A. Ribas, B. Comin-Anduix, and B. Chmielowski Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma Clin Cancer Res 15 2009 6267
38. J.A. Westwood, and M.H. Kershaw Genetic redirection of T cells for cancer therapy J Leukoc Biol 87 2010 791
39. B.G. Till, M.C. Jensen, and J. Wang Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells Blood 112 2008 2261
40. J.R. Park, D.L. Digiusto, and M. Slovak Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma Mol Ther 15 2007 825
41. C.H. Lamers, S. Sleijfer, and A.G. Vulto Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience J Clin Oncol 24 2006 e20
42. L.A. Johnson, R.A. Morgan, and M.E. Dudley Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Blood 114 2009 535
43. R.A. Morgan, M.E. Dudley, and J.R. Wunderlich Cancer regression in patients after transfer of genetically engineered lymphocytes Science 314 2006 126
44. M.A. Pule, B. Savoldo, and G.D. Myers Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma Nat Med 14 2008 1264
45. M.H. Kershaw, J.A. Westwood, and L.L. Parker A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer Clin Cancer Res 12 2006 6106
46. Q. Ma, R.M. Gonzalo-Daganzo, and R.P. Junghans Genetically engineered T cells as adoptive immunotherapy of cancer Cancer Chemother Biol Response Modif 20 2002 315
47. R.S. Warren, G.A. Fisher, and E.K. Bergsland Clinical studies of regional and systemic gene therapy with autologous CC49-z modified T cells in colorectal cancer metastatic to the liver Cancer Gene Ther 5 1998 S1
48. S. Pilon-Thomas, A. Mackay, and N. Vohra Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma J Immunol 184 2010 3442
49. D.H. Lynch The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer Immunol Rev 222 2008 277
50. F.H. Igney, C.K. Behrens, and P.H. Krammer Tumor counterattack: Concept and reality Eur J Immunol 30 2000 725
51. F.H. Igney, and P.H. Krammer Tumor counterattack: Fact or fiction? Cancer Immunol Immunother 54 2005 1127
52. A.E. Ryan, F. Shanahan, and J. O'Connell Addressing the "Fas counterattack" controversy: Blocking Fas ligand expression suppresses tumor immune evasion of colon cancer in vivo Cancer Res 65 2005 9817
53. P.H. Krammer CD95's deadly mission in the immune system Nature 407 2000 789
54. A. Khar, C. Varalakshmi, and B.V. Pardhasaradhi Depletion of the natural killer cell population in the peritoneum by AK-5 tumor cells overexpressing Fas-ligand: A mechanism of immune evasion Cell Immunol 189 1998 85
55. K. Okada, K. Komuta, and S. Hashimoto Frequency of apoptosis of tumor-infiltrating lymphocytes induced by Fas counterattack in human colorectal carcinoma and its correlation with prognosis Clin Cancer Res 6 2000 3560
56. Z. Mahmood, and Y. Shukla Death receptors: Targets for cancer therapy Exp Cell Res 316 2010 887
57. E. Furuta, H. Okuda, and A. Kobayashi Metabolic genes in cancer: Their roles in tumor progression and clinical implications Biochim Biophys Acta 1805 2010 141
58. I. Alagkiozidis, A. Facciabene, and C. Carpenito Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18 J Transl Med 7 2009 104
59. L. Lahiry, B. Saha, and J. Chakraborty Theaflavins target Fas/caspase-8 and Akt/pBad pathways to induce apoptosis in p53-mutated human breast cancer cells Carcinogenesis 31 2010 259
60. T. Osada, D. Hsu, and S. Hammond Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody Br J Cancer 102 2010 124
61. K.A. Chester, L. Robson, and P.A. Keep Production and tumour-binding characterization of a chimeric anti-CEA Fab expressed in Escherichia coli Int J Cancer 57 1994 67
62. K. Brischwein, B. Schlereth, and B. Guller MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors Mol Immunol 43 2006 1129
63. H. Perlman, L.J. Pagliari, and C. Georganas FLICE-inhibitory protein expression during macrophage differentiation confers resistance to Fas-mediated apoptosis J Exp Med 190 1999 1679
64. C. Gratas, Y. Tohma, and E.G. Van Meir Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors Brain Pathol 7 1997 863
65. C. Gutierrez-Steil, T. Wrone-Smith, and X. Sun Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B-irradiated psoriatic plaques express Fas ligand (CD95L) J Clin Invest 101 1998 33
66. L. Peduto Eberl, L. Guillou, and E. Saraga Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas Int J Cancer 81 1999 772
67. H. Rabinowich, T.E. Reichert, and Y. Kashii Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes J Clin Invest 101 1998 2579
68. K. Shiraki, N. Tsuji, and T. Shioda Expression of Fas ligand in liver metastases of human colonic adenocarcinomas Proc Natl Acad Sci USA 94 1997 6420
69. S. Strand, W.J. Hofmann, and H. Hug Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: A mechanism of immune evasion? Nat Med 2 1996 1361
70. H. Ungefroren, M. Voss, and M. Jansen Human pancreatic adenocarcinomas express Fas and Fas ligands yet are resistant to Fas-mediated apoptosis Cancer Res 58 1998 1741
71. M.E. Peter, and P.H. Krammer Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis Curr Opin Immunol 10 1998 545
72. S.P. Cullen, M. Brunet, and S.J. Martin Granzymes in cancer and immunity Cell Death Differ 17 2010 616
73. F. Micucci, A. Zingoni, and M. Piccoli High-efficient lentiviral vector-mediated gene transfer into primary human NK cells Exp Hematol 34 2006 1344
74. M. Gossen, and H. Bujard Tight control of gene expression in mammalian cells by tetracycline-responsive promoters Proc Natl Acad Sci U S A 89 1992 5547
75. A.K. Wege, W. Ernst, and J. Eckl Humanized tumor mice: A new model to study and manipulate the immune response in advanced cancer therapy Int J Cancer 2011 May 4 10.1002/ijc.26159 [Epub ahead of print]